Letter to Shareholders from CEO Dr. Ryan Saadi

Core Viewpoint - Tevogen is focused on evolving into a sustainable, revenue-generating healthcare enterprise through strategic initiatives, including potential acquisitions to enhance its immunotherapy and artificial intelligence platforms [1][2]. Group 1: Strategic Initiatives - The company is actively evaluating potential acquisitions that are expected to operate as subsidiaries, generating positive cash flow and returns on invested capital over time [2][3]. - Preliminary evaluations suggest that the combined entities under consideration may generate aggregate annual revenues exceeding $50 million, aligning with the company's disciplined growth strategy [3]. Group 2: Commitment to Innovation - Tevogen emphasizes that innovation and affordability can coexist, maintaining a commitment to disciplined capital allocation, operational efficiency, and long-term shareholder value creation [4]. - The company aims to develop accessible immunotherapies while strengthening its financial foundation through strategic initiatives [4]. Group 3: Company Overview - Tevogen is a healthcare enterprise built on principles of affordability, efficiency, and scientific rigor, leveraging artificial intelligence and precision T cell therapy platforms [5]. - The company's lead initiative, Tevogen Bio, has completed a proof-of-concept clinical trial demonstrating the potential of its proprietary ExacTcell™ platform across various therapeutic areas [6]. Group 4: Future Directions - Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation and broaden patient access [8].